#	Pagina
attuale pagina	/open-h2020/projects/226676/index.html
-1	/open-h2020/per-topic/partite/list/index.html

Opendata, web and dolomites

ENDFLU SIGNED

Evaluation of ratioNally Designed Influenza vaccines

Total Cost €

EC-Contrib. €

Partnership

Views

ENDFLU project word cloud

Explore the words cloud of the ENDFLU project. It provides you a very rough idea of what is the project "ENDFLU" about.

candidates clinically biochemical demonstration cell fueled manifestations optimized indian achievements scientific immunity biophysical h5 enter elicit constructs encoding vaccine ing model generation epitopes vaccination protective clade mva india artificial gmp efficacy humoral rationally select world protein polyepitope infection hemagglutinin pandemic stem optimize formulation safety conserved endflu human seeds broadly strategies trial head chim m2e surface nanoparticles adoption ferrets advocacy mediated complementary create manufacturing expressed criteria either designed toward internal mice combat repository rational induces influenza cross optimal construct clinical followed assessing immunogenicity expertise functional worldwide plan proteins compliant combined combination dose encode fusions na

Project "ENDFLU" data sheet

The following table provides information about the project.

Coordinator	STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER Organization address address: BUNTEWEG 2 city: HANNOVER postcode: 30559 website: www.tiho-hannover.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Total cost	14˙444˙867 €
EC max contribution	8˙646˙254 € (60%)
Programme	1. H2020-EU.3.1.2. (Preventing disease)
Code Call	H2020-SC1-2019-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-04-01 to 2025-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER Organization address address: BUNTEWEG 2 city: HANNOVER postcode: 30559 website: www.tiho-hannover.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANNOVER)	coordinator	1˙234˙225.00
2	CURVE CLINICAL BV CURVE CLINICAL BV Organization address address: JOOP GEESINKWEG 701 2E ETAGE city: AMSTERDAM DUIVENDRECHT postcode: 1114 AB website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM DUIVENDRECHT)	participant	3˙364˙571.00
3	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 website: www.uni-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	2˙342˙075.00
4	VIB VIB Organization address address: RIJVISSCHESTRAAT 120 city: ZWIJNAARDE - GENT postcode: 9052 website: www.vib.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (ZWIJNAARDE - GENT)	participant	608˙750.00
5	UNIVERSITEIT UTRECHT UNIVERSITEIT UTRECHT Organization address address: HEIDELBERGLAAN 8 city: UTRECHT postcode: 3584 CS website: www.uu.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	participant	435˙707.00
6	LUNDS UNIVERSITET LUNDS UNIVERSITET Organization address address: Paradisgatan 5c city: LUND postcode: 22100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (LUND)	participant	360˙925.00
7	ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE Organization address address: BATIMENT CE 3316 STATION 1 city: LAUSANNE postcode: 1015 website: www.epfl.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (LAUSANNE)	participant	300˙000.00
8	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH Organization address address: Anusandhan Bhawan, Rafi Marg 2 city: NEW DEHLI postcode: 110001 website: www.csir.res.in contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (NEW DEHLI)	participant	0.00
9	INDIAN INSTITUTE OF SCIENCE INDIAN INSTITUTE OF SCIENCE Organization address address: CROSS MALLESHWARAM 18 city: BANGALORE postcode: 560012 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (BANGALORE)	participant	0.00
10	INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH THIRUVANANTHAPURAM INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH THIRUVANANTHAPURAM Organization address address: MARUTHAMALA PO VITHURA city: THIRUVANANTHAPURAM postcode: 695016 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (THIRUVANANTHAPURAM)	participant	0.00
11	MANIPAL ACADEMY OF HIGHER EDUCATION MANIPAL ACADEMY OF HIGHER EDUCATION Organization address address: MANIPAL EDU MADHAV NAGAR city: MANIPAL postcode: 576 104 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (MANIPAL)	participant	0.00
12	MYNVAX PRIVATE LIMITED MYNVAX PRIVATE LIMITED Organization address address: 399 17TH MAIN ROAD 36TH CROSS 4TH T BLOCK JAYANAGAR city: BANGLADORE postcode: 560041 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (BANGLADORE)	participant	0.00
13	SETH G S M COLLEGE AND K E M HOSPITAL DIAMOND JUBILEE SOCIETY SETH G S M COLLEGE AND K E M HOSPITAL DIAMOND JUBILEE SOCIETY Organization address address: ACHARYA DONDE MARG PAREL city: MUMBAI postcode: 400012 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (MUMBAI)	participant	0.00
14	TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE Organization address address: NCR BIOTECH SCIENCE CLUSTER 3RD MILESTONE HARYANA city: FARIDABAD postcode: 121001 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (FARIDABAD)	participant	0.00

Map

Project objective

ENDFLU will develop three complementary next-generation influenza vaccination strategies for the world, fueled by the unique combined expertise of Indian and European partners in rational vaccine design and development: • Create a repository of pre-pandemic GMP-compliant MVA-based vaccine seeds, each encoding an influenza hemagglutinin (HA), based on European partners demonstration of clinical safety and cross-clade immunogenicity of MVA-H5. • Optimize and select protein- and MVA-based constructs developed by Indian and European ENDFLU partners, resulting in a rationally combined vaccine formulation that induces broadly protective humoral and cell-mediated immunity against all influenza manifestations. This will be advanced in a Phase I clinical trial and Controlled Human Infection Model (CHIM) study. • Pre-clinically advance other promising protein- and MVA-based constructs toward future development beyond ENDFLU. Constructs to elicit humoral immunity build on rationally-designed and optimized conserved epitopes of influenza surface proteins, HA stem- and HA head-nanoparticles, and NA-M2e fusions either as proteins or MVA expressed. Other MVA-based constructs to elicit cell-mediated immunity will encode conserved internal protein T cell epitopes, as an artificial polyepitope. The best candidates will be selected based on biochemical, biophysical, functional and manufacturing criteria, and immunogenicity and protective efficacy in mice and ferrets. The selected protein-based construct will enter a Part A Phase I clinical trial in India assessing safety, immunogenicity and optimal dose, to be combined with the selected MVA-based construct. This protein-MVA combination will enter a Part B Phase I clinical trial in the EU, assessing safety and immunogenicity, followed by the CHIM study. A dissemination and exploitation plan, and collaboration with key scientific advocacy organizations will facilitate the adoption of ENDFLU achievements to combat influenza worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENDFLU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENDFLU" are provided by the European Opendata Portal: CORDIS opendata.